Ebook: The LDN book: how a little-known generic drug, low dose naltrexone, could revolutionize treatment for autoimmune diseases, cancer, autism, depression, and more

The history and pharmacology of LDN / by J. Stephen Dickson -- Multiple sclerosis and lupus / by Deanna Windham -- Inflammatory bowel disease / by Jill P. Smith and Leonard B. Weinstock -- Chronic fatigue syndrome and fibromyalgia / by Kent Holtorf -- Thyroid disorders / by Kent Holtorf -- Restless legs syndrome / by Leonard B. Weinstock and Trisha L. Myers -- Depression / by Mark Shukhman and Rebecca Shukhman -- Autism spectrum disorder / by Brian D. Udell -- Cancer / by Angus G. Dalgleish with Wai M. Liu.;Low Dose Naltrexone (LDN) holds the potential to help millions of people suffering from various autoimmune diseases and cancers, and even autism, chronic fatigue, and depression, find relief. Administered off-label in small daily doses (0.5 to 4.5 mg), this generic drug is extremely affordable and presents few known side effects. So why has it languished in relative medical obscurity' The LDN Book explains the drug's origins, its primary mechanism, and the latest research from practicing physicians and pharmacists as compiled by Linda Elsegood of The LDN Research Trust, the world's largest LDN charity organization with over 19,000 members worldwide. Featuring ten chapters contributed by medical professionals on LDN's efficacy and two patient-friendly appendices, The LDN Book is a comprehensive resource for doctors, pharmacists, and patients who want to learn more about how LDN is helping people now, and a clarion call for further research that could help millions more.